Drug Trial Radar · NCT07052903
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
2,250
Planned (sponsor's estimate)
Start
Jul 2, 2025
Primary completion
May 28, 2030
Study completion Nov 30, 2032
Sponsor
- Lead sponsor
- Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
- Sponsor type
- Industry
- First posted
- Jul 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to: * Evaluate the efficacy of nucresiran compared to placebo on reducing all-cause mortality and cardiovascular (CV) events * Evaluate the efficacy of nucresiran compared to placebo on additional assessments of CV events and/or death * Evaluate the efficacy of nucresiran compared to placebo on patient-reported health status and health-related quality of life
Conditions
- Transthyretin Amyloidosis With Cardiomyopathy
Interventions
NucresiranDrug
Nucresiran 300 mg administered SC q6M
Sterile Normal Saline (0.9% NaCl)Drug
Sterile Normal Saline (0.9% NaCl) administered SC once q6M
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite outcome of all-cause mortality and recurrent cardiovascular [CV] events (CV hospitalizations and urgent heart failure [HF] visits)Time frame: Baseline to end of double-blind period (estimated 32 months, maximum 5 years)
Locations
267 sites in 36 countries. Site status is shown where the registry gives one.
Clinical Trial Site
La Jolla, California · Recruiting
Clinical Trial Site
Laguna Hills, California · Recruiting
Clinical Trial Site
Stanford, California · Recruiting
Clinical Trial Site
Aurora, Colorado · Recruiting
Clinical Trial Site
Norwich, Connecticut · Recruiting
Clinical Trial Site
Washington D.C., District of Columbia · Recruiting
Clinical Trial Site
Brandon, Florida · Recruiting
Clinical Trial Site
Miami, Florida · Recruiting
Clinical Trial Site
Atlanta, Georgia · Recruiting
Clinical Trial Site
Gainesville, Georgia · Recruiting
Clinical Trial Site
Tucker, Georgia · Recruiting
Clinical Trial Site
Chicago, Illinois · Recruiting
Clinical Trial Site
Evanston, Illinois · Recruiting
Clinical Trial Site
Indianapolis, Indiana · Recruiting
Clinical Trial Site
Indianapolis, Indiana · Recruiting
Clinical Trial Site
Kansas City, Kansas · Recruiting
Clinical Trial Site
Baltimore, Maryland · Recruiting
Clinical Trial Site
Boston, Massachusetts · Recruiting
Clinical Trial Site
Boston, Massachusetts · Recruiting
Clinical Trial Site
Detroit, Michigan · Recruiting
Clinical Trial Site
Rochester, Minnesota · Recruiting
Clinical Trial Site
St Louis, Missouri · Recruiting
Clinical Trial Site
Manhasset, New York · Recruiting
Clinical Trial Site
New York, New York · Recruiting
Clinical Trial Site
New York, New York · Recruiting
Clinical Trial Site
New York, New York · Recruiting
Clinical Trial Site
The Bronx, New York · Recruiting
Clinical Trial Site
Charlotte, North Carolina · Recruiting
Clinical Trial Site
Cleveland, Ohio · Recruiting
Clinical Trial Site
Columbus, Ohio · Recruiting
Clinical Trial Site
Portland, Oregon · Recruiting
Clinical Trial Site
Lancaster, Pennsylvania · Recruiting
Clinical Trial Site
Philadelphia, Pennsylvania · Recruiting
Clinical Trial Site
Charleston, South Carolina · Recruiting
Clinical Trial Site
Austin, Texas · Recruiting
Clinical Trial Site
Dallas, Texas · Recruiting
Clinical Trial Site
Houston, Texas · Recruiting
Clinical Trial Site
Plano, Texas · Recruiting
Clinical Trial Site
Salt Lake City, Utah · Recruiting
Clinical Trial Site
Charlottesville, Virginia · Recruiting
Showing 40 of 267 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.